Signed in
We value your privacy
This site uses cookies to improve your browsing experience, analyze site traffic, and show personalized content.
Welcome to Pump.fun!
Pump lets anyone create coins, giving everyone equal access to buy and sell from the start. Prices can move quickly, so trade carefully.
By clicking this button, you agree to the Terms and Conditions, Privacy Policy, and certify that you are over 18 years old.
We value your privacy
This site uses cookies to improve your browsing experience, analyze site traffic, and show personalized content.
Paired with SOL| No holders yet. | ||||||||||
Retatrutide (LY3437943) is an investigational drug developed by Eli Lilly that holds promise for the treatment of obesity and Type 2 Diabetes. It's a next-generation peptide therapy that functions as a triple agonist, targeting three hormonal pathways involved in hunger regulation, glucose control, and metabolism: GLP-1, GIP, and glucagon receptors.